Nifty Pharma Index Sees One of Its Biggest One-Day Falls; Trump’s 25% Tariff on Indian Imports Hits Pharma!

The Nifty Pharma index tumbled over 3 percent on Friday, hitting an intraday low of 22,122.65, as investor sentiment was rattled by the announcement of new trade tariffs by the United States. The decline came in the wake of US President Donald Trump's decision to impose a 25 percent tariff on Indian imports, sparking fears of a potential impact on the Indian pharmaceutical sector, which plays a crucial role in the global supply of generic medicines.

Nifty Pharma Tanks, Highly Impacted by 25% Trump Tariff on India

Out of the 20 stocks that make up the Nifty Pharma index, 19 were trading in the red, reflecting a broad-based sell-off. The sharpest losses were seen in key players like Aurobindo Pharma, which dropped 5.17% to Rs 1,080.90, followed by Granules India down 4.89% to Rs 451.70, Sun Pharma falling 4.54% to Rs 1,629.30, Gland Pharma slipping 4.32% to Rs 1,975.70 and Dr. Reddy's Laboratories, which declined 3.85% to Rs 1,221.40.

Other notable laggards included Cipla, Lupin, Alkem Laboratories, Divi's Labs, Ajanta Pharma, Zydus Lifesciences, JB Chemicals, Biocon, and Torrent Pharma, each down between 1 to 5 percent.

Interestingly, Mankind Pharma was the only stock in the index to trade in the green, inching up 0.30% to Rs 2,575.00, defying the broader negative trend.

Nifty Pharma Index Latest Trend

On August 1, the Nifty Pharma index witnessed a sharp decline, closing the day at 22,011.70, down by 759.35 points or 3.33%. This significant drop marked one of the steepest single-day falls for the index in recent weeks, reflecting a broad-based sell-off across major pharmaceutical stocks.

The index had opened the session at 22,696.25, slightly below its previous close of 22,771.05. Despite a brief attempt to recover, hitting an intraday high of 22,705.95, Nifty Pharma eventually slipped to a low of 21,972.65 before settling near the day's bottom.

From a broader perspective, the Nifty Pharma index remains volatile, currently trading below its 52-week high of 23,907.90, but still well above its 52-week low of 19,121.10.

The panic in the market stemmed from concerns over the potential implications of the newly announced US tariffs on Indian pharmaceutical exports. The United States depends significantly on India for its supply of generic drugs, sourcing nearly 50 percent of its needs from Indian manufacturers.

"India's pharmaceutical industry, which supplies 40% of all non-patented medicines sold in the US, could also be hard hit, although the full effect will be unclear until a US "Section 232" investigation of the industry - to assess the effect of imports on national security - is complete," Bloomberg report stated.

Namit Joshi, Chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil)while speaking to news agency ANI, highlighted India's crucial role in the US drug supply chain. He stated that India supplies nearly 47% of the US's pharmaceutical needs, particularly in generic drugs. Joshi warned that any disruption could lead to increased drug prices and shortages in the US.

However, despite the alarming headlines, many analysts believe that the actual risk of near-term tariff implementation on Indian pharma is relatively low. They argue that due to the structural dependence of the US healthcare system on affordable Indian generics, imposing such tariffs could be counterproductive and unsustainable in the long run.